JOM Group: Recession to slow Germany's advertising market in 2023
(Hamburg, Germany): The German advertising market could have succeeded in returning to its pre-Covid-19 level as early as in 2022, and then pushed on to new heights in 2023.
However, as is generally well known, external factors like the Ukraine conflict and persisting supply bottlenecks have prevented this development.
The experts from the JOM Group, agency for hybrid marketing communication, therefore assess that net advertising investment in 2022 only increased by some 1.2 per cent. After a good start to the year, investments fell significantly below the level of the previous year, especially during the second half of the year.
The JOM Group is forecasting even weaker growth of around 0.5 per cent for 2023. That would bring the total volume in the market to around 22.7 billion euro.
Stronger focus on sales in communication
In a weak economic environment, household consumption will also continue to decline in the coming year. In combination with continued high inflation rates, the focus on sales in communication is therefore shifting more strongly into the foreground. This is something that performance-focused online channels and the entire retail media sector benefit from on the one hand, and conventional media, such as radio and outdoor advertising, on the other.
Structurally, budgets are likely to continue to shift from conventional TV to digital moving image channels. This is primarily because platforms like Amazon Freevee, Netflix and Disney+ are opening up to advertising communication, and secondly because emerging moving image platforms like Twitch are constantly evolving.
Significant shifts will also take place in the area of conventional flyers. According to the JOM Group, increased printing and distribution costs are prompting a redistribution with a focus on digital advertising channels.
The first four months will be decisive
“We estimate that the first four months of 2023 will lead the way, because this is when consumers will feel the full impact of many of the effects of inflation on their pockets. The advertising volumes at the beginning of the year may even turn out to be comparatively high as a result. The return on investment and the volumes that the companies' development in sales still allow will then be decisive,” explains Volker Neumann, Managing Director JOM Group.
Kontakter
Shari Luening
Tel: +49 (0)40-27822-0
Email: shari.luening@jom-group.com
Web: http://www.jom-group.com
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom
